Funding for this research was provided by:
Mitsubishi Foundation (30325)
Received: 24 February 2020
Accepted: 27 June 2020
First Online: 6 July 2020
Ethics approval and consent to participate
: The protocol of this study was reviewed and approved by the Institutional Review Board of the Chiba University School of Medicine (ID, 3129). We provided participants with a letter of informed consent that detailed the study’s purpose and assured confidentiality concerning any personal information, and informed participants that completing and mailing back the questionnaire were considered to reflect written informed consent regarding participation in this study.
: Not applicable.
: TH has received research support from Bracket global company. MI received consultant fees from Janssen, Eli Lilly, Otsuka, and Meiji Seika Pharma and honoraria from Janssen Pharmaceutical, Eli Lilly, Otsuka, Meiji Seika Pharma, Astellas, Dainippon Sumitomo, Ono, Mochida, MSD, Eisai, Daiichi-Sankyo, Novartis, Teijin, Shionogi, Hisamitsu, and Asahi Kasei. No potential conflict of interest was reported by the other authors.